Arthritis and Lupus Drugs Pulled Off by Pharma Companies

.

Arthritis and Lupus Drugs Pulled Off by Pharma Companies

Following many deaths, rheumatoid arthritis and lupus drugs are being pulled off by Swiss pharmaceutical companies Roche and Biogen. After being observed by monitoring board, the two drugs were found to be immensely infectious and even deadly in some cases.

Ocrelizumab is still reportedly being tested for people who suffer from relapsing remitting multiple sclerosis. The expected sale of 800 million francs is therefore being denied by Roche. Zurich exchange reported a dip of 0.6% at 179.60 Swiss francs in sales of Roche.

Roche had said that before the drug was proved to be causing some serious infections, earlier last year, at the last stage of its trail, was confirmed that it had a powerful impact on curbing the effect of rheumatoid arthritis.

Roche cited a review which said, "The safety risk outweighs the benefits observed in these specific patient populations at this time after detecting serious and opportunistic infections, some of which were fatal".

National Rheumatoid Arthritis Society states that Rheumatoid arthritis is detected in 20 million people and results in stiff, swollen and painful joints after inflation caused by deficiency of immunity.


Latest News

PPIC’s Poll Reveals Californians Divided in Opinion on Climate Change Impacting
Chairman Says the Boeing Company May have to Move Some Operations Overseas if Ex
Facebook Second Quarter Earnings Surpass Analysts’ Expectations but Growing Expe
Overcharging Scandal Takes a Toll on Whole Foods Earnings
Yelp Trims Third Quarter Earnings Forecast Also Announces Departure of Its Chair
Solvay, the Belgian Chemical Group to Acquire U.S. Cytec for $5.5 billion
Reports Say Amazon Suggests Dividing Airspace into Zones for Delivery Drones
Federal Reserve Expected to Stay Focused on Rate Hike Plan in September
Oil Prices Drop Near Four-Month Low as Supply Glut and Chinese Economy Increases
Reportedly A.G. Lafley to Pass Reigns of P&G CEO to David Taylor
Baidu Profits in Second Quarter Offset by Higher Expenses
Economists Predict Solid Revenue Growth for Vermont